SCHEMBL900013

SCHEMBL900013

CC(C)c1cc(C2CC3CC2CC3C(c2ccc(O)c(C(C)C)c2)c2ccc(O)c(C(C)C)c2)ccc1O

nearest known ligand 0.35

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.35
MEN1 O00255 1/20 0.35
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.35
GABRA1 P14867 2/20 0.31
GABRB2 P47870 2/20 0.31
THRA P10827 3/20 0.31
THRB P10828 3/20 0.31
HSP90AA1 P07900 3/20 0.30
HSP90AB1 P08238 3/20 0.30
ALDH1A1 P00352 1/20 0.30
ALOX12 P18054 1/20 0.30
HTT P42858 1/20 0.30
HIF1A Q16665 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL899694 0.87 MEN1 (0.42) GAAMEN1POLBKMT2AGABRA1
SCHEMBL899831 0.83 MEN1 (0.38) GAAMEN1POLBKMT2A
SCHEMBL9608263 0.83 MEN1 (0.38) GAAMEN1POLBKMT2A
SCHEMBL902914 0.83 MEN1 (0.38) GAAMEN1POLBKMT2A
SCHEMBL903145 0.81 ESR1 (0.33) GAAMEN1POLBKMT2A
SCHEMBL898980 0.81 GABRA1 (0.41) GAAMEN1POLBKMT2AGABRA1
SCHEMBL9608268 0.80 MEN1 (0.39) GAAMEN1POLBKMT2A
SCHEMBL899819 0.78 ESR1 (0.33) GAAMEN1POLBKMT2AALDH1A1
SCHEMBL9608267 0.77 PTGS1 (0.31) GAAMEN1POLBKMT2A
SCHEMBL899009 0.75 ESR1 (0.33) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9261781-B2 Preparation of norbornane-based PAC ballasts SUMITOMO BAKELITE CO., LTD. (JP) 2016-02-16 US claimed
US-20130323640-A1 Preparation of Norbornane-based PAC Ballasts SUMITOMO BAKELITE CO., LTD. (JP) 2013-12-05 US claimed
US-9261781-B2 Preparation of norbornane-based PAC ballasts SUMITOMO BAKELITE CO., LTD. (JP) 2016-02-16 US disclosed
US-20130323640-A1 Preparation of Norbornane-based PAC Ballasts SUMITOMO BAKELITE CO., LTD. (JP) 2013-12-05 US disclosed
US-8530133-B2 Preparation of norbornane-based PAC ballasts PROMERUS, LLC (US) 2013-09-10 US disclosed
EP-2622410-A1 NORBORNANE-BASED PAC BALLAST AND POSITIVE-TONE PHOTOSENSITIVE RESIN COMPOSITION ENCOMPASSING THE PAC Promerus, LLC (US) 2013-08-07 EP disclosed
US-20120135352-A1 Preparation of Norbornane-based PAC Ballasts PROMERUS LLC (US) 2012-05-31 US disclosed
WO-2012044719-A1 NORBORNANE-BASED PAC BALLAST AND POSITIVE-TONE PHOTOSENSITIVE RESIN COMPOSITION ENCOMPASSING THE PAC PROMERUS LLC (US) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135352-A1 Preparation of Norbornane-based PAC Ballasts NBAS, PHB2, BDNF GAA 1663/4885MEN1 2147/4885POLB 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.